Aspirin and Preeclampsia

RecruitingPhase 4

Aspirin to Prevent Cardiac Dysfunction in Preeclampsia

Who can join

Ages 18 to 45 · Women

Full eligibility criteria

Inclusion Criteria:

1. Pregnant Adults between 18 and 45 years of age
2. Diagnosed with preeclampsia
3. Presenting for delivery with a singleton gestation.

Exclusion Criteria:

1. We will exclude patients in labor
2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
3. Plan to deliver outside of the participating site
4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
5. Aspirin allergy
6. Clear indication for aspirin therapy or contraindication to aspirin therapy
7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
9. Those who cannot provide consent

About the study

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

What is being tested

Aspirin 81 mg (drug)
Placebo (drug)

Sponsor: University of Chicago · Participants: 180 · Started: Feb 15, 2021

Contact the study team

Sajid Shahul, MD, PhD · Phone: 773-398-2956
Colleen Duncan, RN · Phone: 7738342892

Official record on ClinicalTrials.gov — NCT04479072

Locations in the U.S.

Illinois

University of Chicago Hospital, Chicago

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.